This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Yaguang Si
Senior Director Biology at FogPharma


With over 17 years of experience in cell biology and oncology drug discovery, Yaguang brings a deep expertise that spans from target validation to Investigational New Drug (IND) applications. As Senior Director of Biology at FogPharma, he was instrumental in co-leading the discovery of FOG-001, a pioneering Helicon™ peptide inhibitor aimed at the beta-catenin/TCFs interaction—a key pathway in cancers with dysregulated Wnt signaling. In this role, Yaguang oversaw all preclinical biology activities of the FOG-001 program, leading to the successful IND submission in 2023. Before his tenure at Fog Pharmaceuticals, Yaguang dedicated over eight years to Agios Pharmaceuticals. There, he played a pivotal role in the oncology target validation team, and also contributed to the discovery biology of mitapivat (PYRUKYND®) and the translational biology for ivosidenib (TIBSOVO®). Yaguang holds a Ph.D. in Biology from Tufts University and a B.S. from Fudan University.

Agenda Sessions

  • Anti-tumor Activities of HeliconTM Peptide Inhibitors of β-catenin/TCF Interaction in Cancer Patient-derived Xenograft Models